The opportunity and business imperative to develop innovative New Chemical Entities (NCEs)

The major shift in strategy has required fundamental cultural and organisational change.  Schwarz moved quickly and developed four programmes in Phase II, and one in Phase III; a major achievement for an organisation so new to the demanding world of NCE development.  However, it was clear that there were opportunities to improve efficiency and effectiveness.  The systems that had been in place for product development were not as efficient or effective as they needed to be with the increasingly successful development pipeline.  One of the areas where Schwarz Pharma recognised the need and has been able to improve in the last two years, to become truly competitive, is Clinical Trial Supplies (CTS).

In late 2002 Schwarz Pharma was planning another Phase III Clinical Trial.  CTS was desperately short of capacity.  Outsourcing seemed to be the answer, as has been the trend within many other pharmaceutical R&D organisations, but the cost of outsourcing was four times what had been originally budgeted.

To read the case study in full, please click on the pdf link below:

Competitive Clinical Supplies.pdf